Malin Life Sciences Holdings Ltd

Average Profitability
<0.0001%
Insider Buys Quantity
13
Insider Buys Sum
$11.07M
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Malin Life Sciences Holdings Ltd

The largest purchase of all time was on 2022-08-08 and amounted to 2150000 shares of Poseida Therapeutics, Inc. for $7.53M.

Biography of Malin Life Sciences Holdings Ltd

No biography is available at this moment.

2022-08-08PurchasePoseida Therapeutics, Inc.
PSTX
2.15M
2.6659%
$3.50$7.53M+0.14%
2021-12-06PurchasePoseida Therapeutics, Inc.
PSTX
10 percent owner
1,828
0.003%
$6.90$12,613-43.32%
2021-12-02PurchasePoseida Therapeutics, Inc.
PSTX
10 percent owner
4,296
0.0065%
$6.88$29,550-47.09%
2021-12-01PurchasePoseida Therapeutics, Inc.
PSTX
10 percent owner
18,365
0.0295%
$6.85$125,806-44.07%
2021-11-30PurchasePoseida Therapeutics, Inc.
PSTX
10 percent owner
28,592
0.0451%
$6.85$195,838-45.04%
2021-11-29PurchasePoseida Therapeutics, Inc.
PSTX
10 percent owner
11,057
0.0177%
$6.89$76,209-44.56%
2021-11-26PurchasePoseida Therapeutics, Inc.
PSTX
10 percent owner
27,251
0.0433%
$6.81$185,492-44.23%
2021-11-24PurchasePoseida Therapeutics, Inc.
PSTX
10 percent owner
1,054
0.0016%
$6.89$7,260-46.8%
2021-11-23PurchasePoseida Therapeutics, Inc.
PSTX
10 percent owner
14,625
0.0227%
$6.77$98,989-45.35%
2021-11-19PurchasePoseida Therapeutics, Inc.
PSTX
10 percent owner
11,104
0.0174%
$7.44$82,650-49.74%
2021-11-18PurchasePoseida Therapeutics, Inc.
PSTX
10 percent owner
71,312
0.1129%
$7.18$511,685-47.31%
2021-11-17PurchasePoseida Therapeutics, Inc.
PSTX
10 percent owner
280,384
0.4549%
$7.21$2.02M-46.27%
2021-11-16PurchasePoseida Therapeutics, Inc.
PSTX
10 percent owner
27,680
0.0441%
$7.17$198,383-46.87%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.